Literature DB >> 20189050

Quality of life in CKD patients treated with erythropoiesis-stimulating agents.

Patrick S Parfrey, Tyler Wish.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20189050     DOI： 10.1053/j.ajkd.2009.12.014

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  4 in total

1.  A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE.

Authors:  Simon D Roger; Sarbjit V Jassal; Michael C Woodward; Steven Soroka; Lawrence P McMahon
Journal:  Int Urol Nephrol       Date:  2013-08-28       Impact factor: 2.370

2.  Comparison of Hemoglobin Levels Before and After Hemodialysis and Their Effects on Erythropoietin Dosing and Cost.

Authors:  Mohammad Mahdi Sagheb; Mohammad Amin Fallahzadeh; Alireza Moaref; Mohammad Hossein Fallahzadeh; Banafshe Dormanesh
Journal:  Nephrourol Mon       Date:  2016-06-29

3.  Chapter 3: Use of ESAs and other agents to treat anemia in CKD.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-08

Review 4.  Management of anemia in patients with diabetic kidney disease: A consensus statement.

Authors:  Sarita Bajaj; Brij Mohan Makkar; Vinod K Abichandani; Pradeep G Talwalkar; Banshi Saboo; S S Srikanta; Ashok Das; Sruti Chandrasekaran; P Venkata Krishnan; Arun Shah; Georgi Abraham; Pankaj Tikku; Sushil Kumar
Journal:  Indian J Endocrinol Metab       Date:  2016 Mar-Apr
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.